T Buclin

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. ncbi request reprint The importance of assessing the dose actually administered in pharmacokinetic trials
    Thierry Buclin
    Division of Clinical Pharmacology and Toxicology, Beaumont 633, University Hospital of Lausanne CHUV, 1011 Lausanne, Switzerland
    Clin Pharmacol Ther 77:235-40. 2005
  2. pmc Two cases of "cannabis acute psychosis" following the administration of oral cannabis
    Bernard Favrat
    Unité de Médecine du Trafic, Institut Universitaire de Medecine Legale, 1005 Lausanne, Switzerland
    BMC Psychiatry 5:17. 2005
  3. ncbi request reprint Estimation of glomerular filtration rate by sinistrin clearance using various approaches
    T Buclin
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Ren Fail 20:267-76. 1998
  4. ncbi request reprint [The blood-brain barrier: recent insights]
    T Buclin
    Division de pharmacologie et toxicologie cliniques, Departement de Medecine, Hôpital Beaumont CHUV, 1011 Lausanne
    Rev Med Suisse 1:959-63. 2005
  5. ncbi request reprint Diet acids and alkalis influence calcium retention in bone
    T Buclin
    Division of Clinical Pharmacology, University Hospital CHUV, Lausanne, Switzerland
    Osteoporos Int 12:493-9. 2001
  6. pmc Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir
    N Perrottet
    Division of Clinical Pharmacology and Toxicology Département de Médecine, Hôpital de Beaumont 06, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Antimicrob Agents Chemother 53:3017-23. 2009
  7. pmc Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
    N Widmer
    Division of Clinical Pharmacology, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Br J Cancer 98:1633-40. 2008
  8. ncbi request reprint Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry
    S Colombo
    Division de pharmacologie clinique, Laboratoire BH 18 218, Departement de Medecine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne CHUV, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 819:259-76. 2005
  9. pmc Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein
    N Widmer
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Br J Clin Pharmacol 62:97-112. 2006
  10. ncbi request reprint Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients
    C Robatel
    Division of Clinical Pharmacology, Department of Medicine, University Hospital, Lausanne, Switzerland
    J Clin Pharmacol 43:1329-40. 2003

Detail Information

Publications82

  1. ncbi request reprint The importance of assessing the dose actually administered in pharmacokinetic trials
    Thierry Buclin
    Division of Clinical Pharmacology and Toxicology, Beaumont 633, University Hospital of Lausanne CHUV, 1011 Lausanne, Switzerland
    Clin Pharmacol Ther 77:235-40. 2005
  2. pmc Two cases of "cannabis acute psychosis" following the administration of oral cannabis
    Bernard Favrat
    Unité de Médecine du Trafic, Institut Universitaire de Medecine Legale, 1005 Lausanne, Switzerland
    BMC Psychiatry 5:17. 2005
    ..Cannabis is the most commonly used illegal drug and its therapeutic aspects have a growing interest. Short-term psychotic reactions have been described but not clearly with synthetic oral THC, especially in occasional users...
  3. ncbi request reprint Estimation of glomerular filtration rate by sinistrin clearance using various approaches
    T Buclin
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Ren Fail 20:267-76. 1998
    ..D/AUC represents the most advisable approach for snapshot renal testing in subjects or patients without important renal impairment...
  4. ncbi request reprint [The blood-brain barrier: recent insights]
    T Buclin
    Division de pharmacologie et toxicologie cliniques, Departement de Medecine, Hôpital Beaumont CHUV, 1011 Lausanne
    Rev Med Suisse 1:959-63. 2005
    ..Genetic polymorphisms affecting transporters may modulate the brain exposure to drugs in selected individuals. Such observations improve our understanding of a key mechanism governing clinical neuro-psychopharmacology...
  5. ncbi request reprint Diet acids and alkalis influence calcium retention in bone
    T Buclin
    Division of Clinical Pharmacology, University Hospital CHUV, Lausanne, Switzerland
    Osteoporos Int 12:493-9. 2001
    ..Further studies are needed to determine the clinical impact of dietary counseling for avoiding diet acids as a preventive measure against osteoporosis...
  6. pmc Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir
    N Perrottet
    Division of Clinical Pharmacology and Toxicology Département de Médecine, Hôpital de Beaumont 06, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Antimicrob Agents Chemother 53:3017-23. 2009
    ..However, GCV plasma measurement may still be helpful in specific clinical situations...
  7. pmc Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
    N Widmer
    Division of Clinical Pharmacology, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Br J Cancer 98:1633-40. 2008
    ..Our findings represent additional arguments to further evaluate the usefulness of individualizing imatinib prescription based on a therapeutic drug monitoring programme, possibly associated with target genotype profiling of patients...
  8. ncbi request reprint Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry
    S Colombo
    Division de pharmacologie clinique, Laboratoire BH 18 218, Departement de Medecine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne CHUV, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 819:259-76. 2005
    ....
  9. pmc Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein
    N Widmer
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Br J Clin Pharmacol 62:97-112. 2006
    ....
  10. ncbi request reprint Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients
    C Robatel
    Division of Clinical Pharmacology, Department of Medicine, University Hospital, Lausanne, Switzerland
    J Clin Pharmacol 43:1329-40. 2003
    ..The results indicate that two different therapeutic schedules of meropenem are equally applicable to patients receiving CVVHD: either 750 mg tid or 1500 bid...
  11. doi request reprint An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients
    E Dahmane
    Division of Clinical Pharmacology and Toxicology, Department of Medecine, Lausanne, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 878:3402-14. 2010
    ....
  12. ncbi request reprint Does tenofovir influence efavirenz pharmacokinetics?
    Margalida Rotger
    Institute of Microbiology, University Hospital, Lausanne, Switzerland
    Antivir Ther 12:115-8. 2007
    ..We evaluated the possibility of a pharmacokinetic interaction between TFV and EFV by assessing cross-sectional and longitudinal data in 169 individuals receiving EFV...
  13. ncbi request reprint Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
    Jacques Fellay
    Division of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland
    Lancet 359:30-6. 2002
    ..This variability could have a genetic basis. We did a pharmacogenetics study to analyse the association between response to antiretroviral treatment and allelic variants of several genes...
  14. doi request reprint Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals
    M Arab-Alameddine
    Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Clin Pharmacol Ther 85:485-94. 2009
    ..Therefore, dosage adjustment in accordance with the type of polymorphism (CYP2B6, CYP2A6, or CYP3A4) is required in order to maintain EFV within the therapeutic target levels...
  15. doi request reprint Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients
    N Perrottet
    Division of Clinical Pharmacology and Toxicology, University Hospital CHUV, Lausanne, Switzerland
    J Antimicrob Chemother 61:1332-5. 2008
    ..To determine whether valganciclovir 450 mg every 48 h for cytomegalovirus (CMV) prophylaxis provides appropriate ganciclovir exposure in solid organ transplant recipients during continuous renal replacement therapy (CRRT)...
  16. doi request reprint A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine
    A Fayet
    Division of Clinical Pharmacology and Toxicology, University Hospital of Lausanne, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 877:1057-69. 2009
    ....
  17. ncbi request reprint Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability
    C Marzolini
    Division of Clinical Pharmacology, Department of Medicine, University Hospital of Lausanne (CHUV, Switzerland
    Ther Drug Monit 23:394-8. 2001
    ..Many subjects had plasma levels repeatedly outside the assumed therapeutic range. Dose adjustment based on therapeutic drug monitoring may contribute to optimizing antiretroviral therapy...
  18. ncbi request reprint Specific determination of PAH and its N-acetyl metabolite by HPLC increases the accuracy and precision of PAH clearance measurements
    L A Decosterd
    Departement de Medecine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Ren Fail 20:311-7. 1998
    ..87 +/- 0.13 implying unphysio-logical values (> 1) in some cases. In conclusion HPLC not only enables the simultaneous quantitation of PAH and NAc-PAH, but may also provide more accurate and precise PAH clearance measurements...
  19. ncbi request reprint Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
    Margalida Rotger
    Institute of Microbiology and Section of Infectious Diseases, University Hospital, Lausanne, Switzerland
    Pharmacogenet Genomics 15:1-5. 2005
    ..Efavirenz (EFV) and nevirapine (NVP) are metabolized by cytochrome P450 2B6 (CYP2B6). Allele 516 G>T (Gln172His) is associated with diminished activity of this isoenzyme, and may lead to differences in drug exposure...
  20. ncbi request reprint Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient
    C Robatel
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, Lausanne, Switzerland
    J Antimicrob Chemother 54:269-70. 2004
    ..To determine whether voriconazole dosage adjustment is required during continuous veno-venous haemodiafiltration (CVVHDF)...
  21. ncbi request reprint Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples
    N Perrottet
    Division de pharmacologie clinique, Departement de Medecine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne CHUV, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 852:420-9. 2007
    ..The method has been validated and is currently applied in a clinical study assessing the ganciclovir plasma concentration variability after administration of valganciclovir in a population of solid organ transplant patients...
  22. ncbi request reprint Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection
    N Widmer
    Division de pharmacologie clinique, Laboratoire BH 18 218, Departement de Medecine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne CHUV, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 803:285-92. 2004
    ..7%). The method has been validated and is currently being applied in a clinical study assessing the imatinib plasma concentration variability in a population of chronic myeloid leukemia- and gastro-intestinal stromal tumor-patients...
  23. ncbi request reprint [Antimicrobial agents and renal elimination: towards individual dosage adjustment?]
    C Willi-Robatel
    Division de pharmacologie et toxicologie cliniques, Département des laboratoires, CHUV, Lausanne
    Rev Med Suisse 8:894-900. 2012
    ..The literature has been reviewed and compared to a predictive model of the fraction of drug cleared by the kidney based on the Dettli's principle. Revised drug dosing recommendations integrating these predictive parameters are proposed...
  24. ncbi request reprint Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients
    C Csajka
    Division of Clinical Pharmacology, University Hospital, CHUV, Lausanne, Switzerland
    Eur J Clin Pharmacol 57:723-7. 2001
    ....
  25. ncbi request reprint Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers
    C B Eap
    Departement universitaire de psychiatrie adulte, Hôpital de Cery, Prilly, Lausanne, Switzerland
    Clin Pharmacol Ther 64:52-7. 1998
    ..It is known that CYP2E1 is involved in the activation of many low-molecular-weight toxins and carcinogens and may be involved in the development of alcohol-induced liver disease...
  26. ncbi request reprint [Multiple diseases: should we treat them all?]
    J Biollaz
    Division de pharmacologie et Toxicologie Cliniques CHUV, 1011 Lausanne
    Rev Med Suisse 1:941-7. 2005
    ....
  27. ncbi request reprint The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial
    C Mazzocato
    Division of Palliative Care, University Hospital, Lausanne, Switzerland
    Ann Oncol 10:1511-4. 1999
    ..This study was undertaken to assess the efficacy of morphine on dyspnea and its safety for ventilatory function in elderly advanced cancer patients...
  28. ncbi request reprint [Pharmacovigilance and teratovigilance]
    FranCoise Livio
    Division de pharmacologie et toxicologie cliniques, Hôpital de Beaumont, CHUV, 1011 Lausanne
    Rev Med Suisse 3:238-42. 2007
    ....
  29. ncbi request reprint [Pharmacogenetic testing: soon before every prescription?]
    Thierry Buclin
    Division de pharmacologie et toxicologie cliniques, CHUV, 1011 Lausanne
    Rev Med Suisse 4:1666-70. 2008
    ..Prospective controlled trials are required to evaluate large-scale pharmacogenetic testing in therapeutics. Ethical, social and psychological issues deserve particular attention...
  30. ncbi request reprint Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo
    Sara Colombo
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Pharmacogenet Genomics 15:599-608. 2005
    ..Genetic polymorphism in these genes may be associated with changes in transport function...
  31. ncbi request reprint Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
    Chantal Csajka
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Clin Pharmacol Ther 73:20-30. 2003
    ....
  32. ncbi request reprint Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers
    Chantal Csajka
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Clin Pharmacokinet 41:137-52. 2002
    ..To compare the pharmacokinetic and pharmacodynamic characteristics of angiotensin II receptor antagonists as a therapeutic class...
  33. ncbi request reprint The interpretation of secondary blood markers can get hazardous in case of a discontinuous rhEPO treatment
    Neil Robinson
    Laboratoire Suisse d Analyse du Dopage, Institut Universitaire de Medecine Legale, Rue du Bugnon 21, 1005 Lausanne, Switzerland
    Haematologica 87:ELT28. 2002
  34. ncbi request reprint Composition and cost of drugs stored at home by elderly patients
    Jean Blaise Wasserfallen
    University Hospital CHUV, Lausanne, Switzerland
    Ann Pharmacother 37:731-7. 2003
    ..Excessive prescribing, imperfect therapeutic adherence, treatment modifications after hospitalization, and oversized drug packages result in home storage of leftover drugs, resulting in a waste of healthcare resources...
  35. ncbi request reprint Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence
    Chin B Eap
    Unit of Biochemistry and Clinical Psychopharmacology, University Department of Adult Psychiatry, Cery Hospital, Prilly Lausanne, Switzerland
    Clin Pharmacokinet 41:1153-93. 2002
    ..However, therapeutic drug monitoring can be useful in particular situations. In the case of non-response trough plasma concentrations of 400 microg/L for (R,S)-methadone or 250 microg/L for (R)-methadone might be used as target values...
  36. ncbi request reprint CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene
    Chin B Eap
    Unit of Biochemistry and Clinical Psychopharmacology, Centre of Psychiatric Neurosciences, University Department of Adult Psychiatry, Hôpital de Cery, CH 1008 Prilly Lausanne, Switzerland
    Pharmacogenetics 14:255-60. 2004
    ..The existence of a strong association between the activity of CYP3A and MDR13435 C >T and 2677 G >T polymorphisms appears unlikely, at least in Caucasian populations and/or in the absence of specific environmental factors...
  37. ncbi request reprint Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity
    Chin B Eap
    Unit of Biochemistry and Clinical Psychopharmacology, Centre of Psychiatric Neurosciences, University Department of Adult Psychiatry, Prilly Lausanne, Switzerland
    Eur J Clin Pharmacol 60:237-46. 2004
    ..We investigated whether the oral administration of a low dose (75 micro g) of midazolam, a CYP3A probe, can be used to measure the in vivo CYP3A activity...
  38. ncbi request reprint Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects
    Chin B Eap
    Unit of Biochemistry and Clinical Psychopharmacology, Centre of Psychiatric Neurosciences, University Department of Adult Psychiatry, Hôpital de Cery, 1008 Prilly Lausanne, Switzerland
    Eur J Clin Pharmacol 60:231-6. 2004
    ..We investigated whether differences in pharmacokinetics of midazolam, a CYP3A probe, could be demonstrated between subjects with different CYP3A4 and CYP3A5 genotypes...
  39. ncbi request reprint Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery
    C Marzolini
    Division de pharmacologie clinique, Laboratoire BH 18 218, Departement de Medecine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne CHUV, Switzerland
    J Chromatogr B Analyt Technol Biomed Life Sci 774:127-40. 2002
    ....
  40. ncbi request reprint [Pharmacovigilance]
    F Livio
    Division de pharmacologie et toxicologie cliniques, Département de médecine CHUV, 1011 Lausanne
    Rev Med Suisse 8:116-9. 2012
    ..Topiramate: Evidence of teratogenicity (oral clefts). Valproate: Impaired cognitive development in addition to well-known teratogenicity. Antipsychotics in late pregnancy: A risk of neonatal complications...
  41. ncbi request reprint [Pharmacovigilance update]
    F Livio
    Division de pharmacologie et toxicologie cliniques, Département de médecine CHUV, 1011 Lausanne
    Rev Med Suisse 6:128-31. 2010
    ..Raised concerns of causality between insuline glargine and malignant tumors are not supported by strong evidence. Proton pump inhibitors seem to blunt clopidogrel benefit. Aliskiren can cause angioedema...
  42. ncbi request reprint [Pharmacovigilance update]
    F Livio
    Division de pharmacologie et toxicologie cliniques, Departement de Medecine, CHUV, 1011 Lausanne
    Rev Med Suisse 7:71-4. 2011
    ..The correct use of transdermal patches is reviewed with the example of rivastigmine. Aseptic meningitis is a rare adverse reaction of lamotrigine. An increased risk of fractures after long term use of proton pump inhibitors is suspected...
  43. ncbi request reprint Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor. Synthesis and pharmacological evaluation of a Y2 antagonist
    E Grouzmann
    Division d Hypertension, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Biol Chem 272:7699-706. 1997
    ..48. Thus, to our best knowledge, T4-[NPY(33-36)]4 represents the first potent and selective Y2 antagonist...
  44. ncbi request reprint Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
    Sara Colombo
    Division of Clinical Pharmacology and Toxicology, University Hospital of Bern, Switzerland
    Ther Drug Monit 28:332-8. 2006
    ..For drugs such as EFV or NVP, there may be room for therapeutic drug monitoring improvement using either direct CC determination or other predictive factors such as genotyping of transporters or metabolizing enzyme genes...
  45. ncbi request reprint [Generic drugs and legal incentives: which impact?]
    F Livio
    Division de pharmacologie et toxicologie cliniques, Hôpital de Beaumont, CHUV, Lausanne
    Rev Med Suisse 2:966-9. 2006
    ..The advantages of using International Nonproprietary Names (INN) for drug prescription are discussed. A renewal of prescription habits would be welcomed however several practical issues would have to find rational solutions...
  46. ncbi request reprint Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC
    C Robatel
    Departement de Medecine, Division de pharmacologie clinique, Laboratoire BH 18 218, Centre Hospitalier Universitaire Vaudois CHUV, 1011 Lausanne, Switzerland
    J Pharm Biomed Anal 29:17-33. 2002
    ..The levels of the metabolite UK-1a encountered in this population of patients were higher than those observed in healthy volunteers but was similar to those observed in patients with renal impairment under hemodialysis...
  47. ncbi request reprint [Drugs and breastfeeding: some facts to consider before deciding they are incompatible]
    A Panchaud
    Division de pharmacologie et toxicologie cliniques, CHUV, Lausanne
    Rev Med Suisse 4:540-5. 2008
    ..This article aims to review the facts needed to assess amount of drug exposure to the child and to list the few drugs associated with significant effects on the nursing infant...
  48. pmc NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios
    A Nyeki
    Group of Pharmaceutical Analysis, Section of Pharmacy, University of Lausanne, Lausanne, Switzerland
    Br J Clin Pharmacol 55:62-7. 2003
    ....
  49. ncbi request reprint [Pharmacovigilance update]
    F Livio
    Division de pharmacologie et toxicologie cliniques, CHUV, 1011 Lausanne
    Rev Med Suisse 4:150-4. 2008
    ..Besides biological investigations of questionable relevance and clinical trial of inconstant efficiency towards safety outcomes, the role of pharmacovigilance notifications by practitioners remains of paramount importance...
  50. ncbi request reprint Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation
    Sara Colombo
    Division of Clinical Pharmacology and Toxicology, University Hospital of Lausanne, Institute of Microbiology, Lausanne, Switzerland
    Clin Pharmacol Ther 80:307-18. 2006
    ..Efavirenz, mainly bound to albumin, was included as a control drug...
  51. pmc Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus
    Chantal Csajka
    Division of Clinical Pharmacology, University Hospital, CHUV, Beaumont 633, Lausanne 1011, Switzerland
    Antimicrob Agents Chemother 48:3226-32. 2004
    ..The high interpatient pharmacokinetic variability represents an argument for therapeutic drug monitoring...
  52. ncbi request reprint Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days
    Sylvie Vouillamoz-Lorenz
    Centre Pluridisciplinaire d Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Anticancer Res 23:2757-65. 2003
    ..The fate of platinum delivered by this oral formulation administered at various doses under the 5 or 14 days schedule, has been studied to a limited extent...
  53. pmc Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection
    Sara Colombo
    Division of Clinical Pharmacology and Toxicology, University Hospital, CHUV, Lausanne 1011, Switzerland
    Antimicrob Agents Chemother 50:3801-8. 2006
    ..This population pharmacokinetic model, together with therapeutic drug monitoring and Bayesian dosage adaptation, can be helpful in the selection and adaptation of ATV doses...
  54. doi request reprint Pregnancy outcome following maternal exposure to statins: a multicentre prospective study
    U Winterfeld
    STIS and Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    BJOG 120:463-71. 2013
    ..This contribution addresses the risk associated with exposure to statins during pregnancy...
  55. ncbi request reprint [Serotonin syndrome: review and case series from the Swiss pharmacovigilance system]
    M Chassot
    Division de pharmacologie et toxicologie cliniques, Departement de Medecine, Hôpital de Beaumont, CHUV, 1011 Lausanne
    Rev Med Suisse 8:2086-90. 2012
    ..We also analyzed the 102 cases notified to Swissmedic from 1998 to 2009, focusing on patients profile and suspected drugs...
  56. ncbi request reprint [The medical advisor: a friend to count on?]
    J Biollaz
    Departement de Medecine, Centre Hospitalier Universitaire Vaudois, Lausanne
    Praxis (Bern 1994) 88:719-25. 1999
    ....
  57. ncbi request reprint [Risk of overtreatment: not to be neglected. The example of antiepileptic drugs]
    L E Rothuizen
    Division de pharmacologie et toxicologie cliniques, Département de médecine Hôpital Beaumont, CHUV, Lausanne
    Rev Med Suisse 2:976-80. 2006
    ..Its prevention requires the recognition of the situations and the understanding of the mechanisms leading to it. The pharmacological treatment of epilepsy exposes to such a risk and serves as an example for its detection and correction...
  58. ncbi request reprint [Trends in drug therapy]
    F Livio
    Division de pharmacologie et toxicologie cliniques, Departement de Medecine, CHUV, Lausanne
    Rev Med Suisse 2:155-9. 2006
    ..Risk-benefit assessment of drugs is a dynamic process. One must keep in mind that the data on the relationship between drugs and the clinical picture are of variable quality and that the size of the risk is often difficult to assess...
  59. ncbi request reprint Disappearance rate of catecholamines, total metanephrines, and neuropeptide Y from the plasma of patients after resection of pheochromocytoma
    E Grouzmann
    Division d Hypertension, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
    Clin Chem 47:1075-82. 2001
    ..We hypothesized that the long persistence of total (sulfate-conjugated plus free) metanephrines in the blood might have a significant diagnostic value...
  60. ncbi request reprint [Will good clinical practice domesticate human research?]
    T Buclin
    Division de pharmacologie et toxicologie cliniques, Hôpital de Beaumont CHUV, Lausanne
    Rev Med Suisse 2:992-6. 2006
    ..No clinical study should be planned without consideration of a series of legal requirements, which are reviewed. Concerns about their practical implications are critically assessed...
  61. doi request reprint Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction
    Aurélie Fayet
    Division of Clinical Pharmacology, Centre Hospitalier Universataire Vaudois, Lausanne, Switzerland
    Ther Drug Monit 30:511-22. 2008
    ....
  62. doi request reprint ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir
    Rubin Lubomirov
    Institute of Microbiology, Service of Infectious Diseases, Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Pharmacogenet Genomics 20:217-30. 2010
    ....
  63. ncbi request reprint Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures
    Sara Colombo
    Division of Clinical Pharmacology and Toxicology, University Hospital of Lausanne, Switzerland
    Antivir Ther 11:53-62. 2006
    ..To assess potential pharmacokinetic (PK) interactions between atazanavir (ATV, 300 mg, once daily) and lopinavir (LPV, 400 mg, twice daily), both boosted by ritonavir (RTV, 100 mg)...
  64. pmc Effect of dronedarone on renal function in healthy subjects
    Yvonne Tschuppert
    Clinical Pharmacology and Toxicology, University Hospital, Lausanne, Switzerland
    Br J Clin Pharmacol 64:785-91. 2007
    ..To assess the effects of dronedarone on renal function and tubular cation handling...
  65. ncbi request reprint Oligoanalgesia in the emergency department: short-term beneficial effects of an education program on acute pain
    Isabelle Decosterd
    Department of Anesthesiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    Ann Emerg Med 50:462-71. 2007
    ..We evaluate the effect of the implementation of guidelines for pain management in ED patients with pain at admission or anytime during their stay in our ED...
  66. ncbi request reprint Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial
    Alice Panchaud
    Unité de nutrition clinique, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Clin Nutr 25:418-27. 2006
    ....
  67. doi request reprint A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites
    Andrea Kuemmerle
    Division de pharmacologie clinique, Departement de Medecine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Cancer Chemother Pharmacol 63:331-41. 2009
    ....
  68. ncbi request reprint Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients
    Sandrine Ostermann
    Multidisciplinary Oncology Center, Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Clin Cancer Res 10:3728-36. 2004
    ....
  69. ncbi request reprint Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers
    Thierry Buclin
    Division of Clinical Pharmacology, University Hospital of Lausanne CHUV, Switzerland
    J Bone Miner Res 17:1478-85. 2002
    ..This study shows that oral delivery of SCT is feasible with reproducible absorption and systemic biological efficacy. Such an oral formulation could facilitate the use of SCT in the treatment of osteoporosis and other bone diseases...
  70. doi request reprint Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
    Andres Pascual
    Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Clin Infect Dis 46:201-11. 2008
    ..Liver disease, age, genetic polymorphism of the cytochrome CYP2C19, and comedications influence voriconazole metabolism. Large variations in voriconazole pharmacokinetics may be associated with decreased efficacy or with toxicity...
  71. ncbi request reprint Transplacental passage of protease inhibitors at delivery
    Catia Marzolini
    Division of Clinical Pharmacology, University Hospital of Lausanne, Lausanne, Switzerland
    AIDS 16:889-93. 2002
    ..The aim of this study was to assess the extent of transplacental passage of PI at delivery...
  72. ncbi request reprint Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients
    Jacques Fellay
    Division of Infectious Diseases, University Hospital of Lausanne, Switzerland
    Eur J Clin Pharmacol 60:865-73. 2005
    ..To measure the in vivo variations of CYP3A activity induced by anti-HIV drugs in human immunodeficiency virus (HIV)1-positive patients...
  73. ncbi request reprint Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC
    Annick Menetrey
    Laboratoire de Toxicologie et Chimie Forensiques LTCF, institut universitaire de médecine légale IUML, Switzerland
    J Anal Toxicol 29:327-38. 2005
    ..This controlled clinical study points out the negative influence on fitness to drive after medium or high dose oral THC or dronabinol...
  74. ncbi request reprint Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients
    Nicole Doser
    AIDS 16:1982-3. 2002
  75. ncbi request reprint Functional consequence of MDR1 expression on imatinib intracellular concentrations
    Nicolas Widmer
    Blood 102:1142. 2003
  76. ncbi request reprint Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
    Catia Marzolini
    Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN 37232, USA
    Clin Pharmacol Ther 75:13-33. 2004
    ..In addition, issues relating to MDR1 haplotypes, environmental factors, and study design, as potential confounding factors of the observed MDR1 polymorphism effect in vivo, are also discussed...
  77. ncbi request reprint A case of voluntary intoxication with efavirenz and lamivudine
    Rémy T Boscacci
    AIDS 20:1352-4. 2006
  78. ncbi request reprint Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients
    Suzie Lavoie
    Center for Psychiatric Neuroscience, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
    Neuropsychopharmacology 33:2187-99. 2008
    ..The improvement of this functional marker may indicate an important pathway towards new therapeutic strategies that target glutathione dysregulation in schizophrenia...
  79. ncbi request reprint Acute pain in adults admitted to the emergency room: development and implementation of abbreviated guidelines
    Emmanuel Tamchès
    Centre interdisciplinaire des urgences, CHUV, Lausanne
    Swiss Med Wkly 137:223-7. 2007
    ..With the aim of improving the care of adult patients with acute pain, we developed and implemented abbreviated clinical practice guidelines (CG) for the staff of nurses and physicians in our hospital's emergency room...
  80. ncbi request reprint NPY Y1 receptor is not involved in the hemodynamic response to an acute cold pressor test in mice
    Claudia Cavadas
    Center for Neurosciences and Cell Biology and Faculty of Pharmacy, University of Coimbra, 3020 123 Coimbra, Portugal
    Peptides 28:315-9. 2007
    ..In conclusion, mice lacking the Y(1) receptor can maintain normal hemodynamic response to an acute activation of the sympathetic system, albeit at the expense of increased catecholamine discharge...
  81. pmc Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods
    Andres Pascual
    Infectious Diseases Service, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, CH 1011 Lausanne, Switzerland
    Antimicrob Agents Chemother 51:137-43. 2007
    ..Simple HPLC and bioassay methods offer new tools for monitoring voriconazole therapy...
  82. ncbi request reprint Impact of the C2/C6 ratio of high-molecular-weight hydroxyethyl starch on pharmacokinetics and blood coagulation in pigs
    Sebastian Schramm
    Department of Anesthesiology, University Hospital Lausanne, Switzerland
    Anesthesiology 107:442-51. 2007
    ..The authors assessed in vivo the effect of a lowered C2/C6 ratio on pharmacokinetic characteristics and the impact on blood coagulation of high-molecular-weight, low-substituted HES...